MRUS

Merus N.V

$27.20

-0.02 (-0.07%)

quotes and stock data delayed 15 minutes

52 wk hi

52 wk low

10.5

30.59

Cash

$190.2M

Burn Rate (Qtr)

$11.7M

Mkt Cap

$859.6m

Avg Volume

216,823

*cash/burn updated:

Q3'20

Company Profile

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Zeno (MCLA-128 - ntibody-dependent cell-mediated cytotoxicity (ADCC))

Neuregulin 1 Fusion Cancers (NRG1) Solid tumors

Phase 1/2

Q2 2021

Update

Clinical program update at a major medical meeting in the second quarter of 2021.

MCLA-158 (Lgr5 x EGFR Biclonics®)

Solid Tumors

Phase 1

TBA

Data readout

Phase 1 trial continues; Update expected by year end

MCLA-145 (CD137 x PD-L1 Biclonics®)